LU LIU^1,2, BIN XIE^1,2, WEI ZHU^1,2, QIUYAN HE^1,2, JIANHUA ZHOU^1,2, SHUANG LIU³, YONGGUANG TAO⁴, DESHENG XIAO^1,2,*

Oncology Research, Vol.31, No.3, pp. 275-286, 2023, DOI:10.32604/or.2023.028227

Abstract Background: Lung cancer is one of the most lethal cancers worldwide, but studies have shown that the higher the expression of programmed cell death protein 1 ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC), the more likely it will benefit from anti-PD-L1 immunotherapy. The purpose of our study was to collect and analyze abundant clinical samples in order to provide evidence for clinicians and patients who might consider anti-PD-L1 immunotherapy while jointly formulating treatment plans. Methods: On the one hand, we obtained cases from The Cancer Genome Atlas (TCGA) database, including 498 lung squamous cell cancer (LUSC) patients and… More >

FRANCISCO RAÚL BORZONE^1,*, MARÍA BELÉN GIORELLO¹, LEANDRO MARCELO MARTINEZ², MARÍA CECILIA SANMARTIN^1,3, LEONARDO FELDMAN⁴, FEDERICO DIMASE⁵, EMILIO BATAGELJ⁶, GUSTAVO YANNARELLI³, NORMA ALEJANDRA CHASSEING^1,*

Oncology Research, Vol.31, No.3, pp. 361-374, 2023, DOI:10.32604/or.2023.028104

Abstract Breast cancer is the predominant form of carcinoma among women worldwide, with 70% of advanced patients developing bone metastases, with a high mortality rate. In this sense, the bone marrow (BM) mesenchymal stem/stromal cells (MSCs) are critical for BM/bone homeostasis, and failures in their functionality, transform the BM into a pre-metastatic niche (PMN). We previously found that BM-MSCs from advanced breast cancer patients (BCPs, infiltrative ductal carcinoma, stage III-B) have an abnormal profile. This work aims to study some of the metabolic and molecular mechanisms underlying MSCs shift from a normal to an abnormal profile in this group of patients.… More >

A.T. Bambara, A.J.K. Nébié, A.C. Sama, F. Akanni, R. Sombié

Psycho-Oncologie, Vol.16, No.4, pp. 365-373, 2022, DOI:10.3166/pson-2022-0204

Abstract The aim of this study was to analyze the expectations of cancer patients from their main caregivers in a resource-limited setting. We also seek to determine the concordance between these expectations and the roles assumed by their main caregivers. In total, 72 dyad volunteers (patient and main caregiver) participated in the study. Patients’ expectations varied according to location (hospital, home, other locations). The agreement between these expectations and the services provided by their main caregivers was poor based on kappa statistic.

Résumé
Cette étude a pour objectif d’analyser les attentes des patients atteints de cancer vis-à-vis de leurs aidants… More >

YANGYI HE^1,2, DAVID SANCHEZ-LORENTE^3,4,5, MELISSA ACOSTA-PLASENCIA¹, MARC BOADA^3,4,5, ANGELA GUIRAO^3,4,5, RAMON M. MARRADES^4,5,6,7, LAUREANO MOLINS^3,4,5, ALFONS NAVARRO^1,4,5,*

BIOCELL, Vol.47, No.5, pp. 951-957, 2023, DOI:10.32604/biocell.2023.027718

Abstract Tumor-secreted extracellular vesicles (EVs) participate in the metastasis process through different mechanisms, including the preparation of the pre-metastatic niche to grant circulating tumor cells (CTCs) implantation and growth. The study of the metastasis process through the analysis of CTCs and tumor-derived EVs is difficult because of the dilution grade of these elements in peripheral blood. In early-stage lung cancer patients, the tumor-secreted products are even more diluted. An attractive strategy in surgical lung cancer patients is to purify them from a pulmonary tumor-draining vein where they are enriched. The information obtained from the analysis of EVs and CTCs purified from… More >

DIEGO HERNANDEZ^1,*, CHIH-YUAN CHENG^1,2, KARLA HERNANDEZ-VILLAFUERTE¹, MICHAEL SCHLANDER^1,2

Oncology Research, Vol.30, No.4, pp. 173-185, 2022, DOI:10.32604/or.2022.027262

Abstract Lung cancer is the most common cancer type worldwide and has the highest and second highest mortality rate for men and women respectively in Germany. Yet, the role of comorbid illnesses in lung cancer patient prognosis is still debated. We analyzed administrative claims data from one of the largest statutory health insurance (SHI) funds in Germany, covering close to 9 million people (11% of the national population); observation period was from 2005 to 2019. Lung cancer patients and their concomitant diseases were identified by ICD-10-GM codes. Comorbidities were classified according to the Charlson Comorbidity Index (CCI). Incidence, comorbidity prevalence and… More >

Lei Hu^1,2,#, Meng Chen^2,3,#, Haiming Dai^2,3,4, Hongzhi Wang^2,3,4,*, Wulin Yang^2,3,4,*

Oncologie, Vol.24, No.4, pp. 803-822, 2022, DOI:10.32604/oncologie.2022.026419

Abstract Background and Aim: Hundreds of consistently altered metabolic genes have been identified in breast cancer (BC), but their prognostic value remains to be explored. Therefore, we aimed to build a prediction model based on metabolism-related genes (MRGs) to guide BC prognosis. Methods: Current work focuses on constructing a novel MRGs signature to predict the prognosis of BC patients using MRGs derived from the Virtual Metabolic Human (VMH) database, and expression profiles and clinicopathological data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Results: The 3-MRGs-signature constructed by SERPINA1, QPRT and PXDNL was found to be an… More >

MOTAWA E. EL-HOUSEINI¹, MOSTAFA S. ARAFAT², AHMED M. EL-HUSSEINY³, ISLAM M. KASEM², MAHMOUD M. KAMEL⁴, AHMED H. EL-HABASHY⁵, MEDHAT M. KHAFAGY⁶, ENAS M. RADWAN⁴, MAHA H. HELAL⁷, MONA S. ABDELLATEIF^1,*

Oncology Research, Vol.29, No.5, pp. 319-329, 2021, DOI:10.32604/or.2022.025249

Abstract Immunotherapy becomes a promising line of treatment for breast cancer (BC) however, its success rate is still limited. Methods: The study was designed to optimize the condition for producing an effective dendritic cell (DCs) based immunotherapy by using DCs and T lymphocytes together with tumor-infiltrating lymphocytes (TILs) and tumor-infiltrating DCs (TIDCs), treated with anti-PD1 and anti-CTLA4 monoclonal antibodies. This mixture of immune cells was co-cultured with autologous breast cancer cells (BCCs) isolated from 26 BC females. Results: There was a significant upregulation of CD86 and CD83 on DCs (P = 0.001 and 0.017, respectively), similarly upregulation of CD8, CD4 and… More >

Xujie Zhou^1,2,3,#, Yuting Sang^1,3,#, Jiajian Chen^1,3, Miao Mo^3,4, Jianjing Hou^1,3, Benlong Yang^1,3,*, Jiong Wu^1,2,3,*

Oncologie, Vol.24, No.3, pp. 451-469, 2022, DOI:10.32604/oncologie.2022.025226

Abstract Background: To compare the time-varying recurrence patterns of different molecular subtypes of breast cancer in the contemporary era with those in the past era. Patients and Methods: This retrospective study included 14627 consecutive invasive breast cancer patients who underwent surgery from 2008 to 2016 at Fudan University Shanghai Cancer Center. We defined the period from 2013 to 2016 as the contemporary era and that from 2008 to 2012 as the past era. Five subtypes were defined according to the immunohistochemistry results. Emphasis was made on the changing patterns of recurrence for patients with different molecular subtypes changed between the two… More >

S. Raguvaran^1,*, S. Anandamurugan², A. M. J. Md. Zubair Rahman³

Intelligent Automation & Soft Computing, Vol.35, No.2, pp. 2171-2187, 2023, DOI:10.32604/iasc.2023.028605

Abstract A customized nutrition-rich diet plan is of utmost importance for cancer patients to intake healthy and nutritious foods that help them to be strong enough to maintain their body weight and body tissues. Consuming nutrition-rich diet foods will prevent them from the side effects caused before and after treatment thereby minimizing it. This work is proposed here to provide them with an effective diet assessment plan using deep learning-based automated medical diet system. Hence, an Enhanced Long-Short Term Memory (E-LSTM) has been proposed in this paper, especially for cancer patients. This proposed method will be very useful for cancer patients… More >

Jianping Xu, Xiaoyan Liu, Sheng Yang, Yuankai Shi

Oncology Research, Vol.28, No.2, pp. 127-133, 2020, DOI:10.3727/096504019X15707896762251

Abstract Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in China, exerts antiangiogenic and antineoplastic function through selectively binding and inhibiting vascular endothelial growth factor receptor 2 (VEGFR-2). In this study, we aimed to explore the efficacy and safety profile of apatinib monotherapy, or combined with chemotherapy or endothelial growth factor receptor (EGFR)-TKI in heavily pretreated non-small cell lung cancer (NSCLC) patients with brain metastases. We performed a retrospective analysis for relapsed NSCLC patients with brain metastases from our institute, who received apatinib (250 mg or 500 mg p.o. qd) monotherapy, or combination with EGFR-TKI or chemotherapy… More >